# A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer

Source: https://onco.cc/trials/nct06747338/  
OnCo record `nct06747338` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing HB1801 in HER2-positive breast cancer, active and no longer recruiting.

## Summary

A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer is a phase 3 interventional study registered as NCT06747338, led by Shanghai JMT-Bio, and active but no longer recruiting on the registry. Official title: A Randomised, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer. Planned enrolment is 520 participants (estimated). The study started in 2024-12-16 and primary completion is expected in 2026-12-16. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06747338
- Phase: 3
- Setting: A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer
- Sponsor: Shanghai JMT-Bio
- Enrolled: 520

## Sources

- ClinicalTrials.gov NCT06747338: https://clinicaltrials.gov/study/NCT06747338

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [HB1801](https://onco.cc/drugs/hb1801/), [KN026](https://onco.cc/drugs/kn026/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)
- key papers: [Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial](https://onco.cc/key-papers/paper-nct06747338-jama-oncol-2026/)

---
JSON: https://onco.cc/api/v1/entities/nct06747338.json